Burrill Starts Cleveland BioLabs (CBLI) at Market Outperform

December 4, 2012 7:18 AM EST Send to a Friend
Get Alerts CBLI Hot Sheet
Price: $0.36 --0%

Rating Summary:
    4 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 1 | Down: 1 | New: 6
Trade CBLI Now!
Join SI Premium – FREE
Burrill initiates coverage on Cleveland BioLabs (NASDAQ: CBLI) with a Market Outperform. PT $4.00.

The firm comments, "We believe that the company's lead program, Entolimod, has the potential to be used as an antidote for the treatment of Acute Radiation Syndrome (ARS). CBLI aims to secure procurement contracts from the U.S. government. Not entirely reliant on government funding, CBLI has initiated a number of oncology programs, which range from pre-clinical testing to Phase 1/2 development."

For an analyst ratings summary and ratings history on Cleveland BioLabs click here. For more ratings news on Cleveland BioLabs click here.

Shares of Cleveland BioLabs closed at $1.31 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Hot New Coverage, New Coverage

Add Your Comment